Breaking News on Biopharmaceutical Development & Manufacturing

Top Headlines

Sanofi signs nanobody drug and tech deal that could earn Ablynx billions

Sanofi has licensed access to Ablynx NV’s nanobody platform as well as candidate drugs in a deal that could earn the Belgian firm billions of euros.

Cancer-fighting combo: mRNA and antibody-focused treatment wins EU patent

Regulators have granted CureVac a European patent for its mRNA vaccine and anti-PD-1 antibody technology designed to prevent and treat cancers and infectious diseases.

update - comment from Unite

GSK says UK manufacturing cuts not Brexit related

GSK has announced a shakeup of its UK network, shelving plans for Ulverston biopharma plant, mooting the sale of its cephalosporin antibiotics business and pledging to invest in HIV and respiratory drug capacity.

Proliant BSA in Asia: China opens door to NZ bovine blood

Following months of importation restrictions, Proliant Biologicals has announced it is eligible to export bovine serum albumin (BSA) from its Feilding, New Zealand-based facility to China.

Update - comments from EMA and EFPIA

EU to probe if drug firms' pre-submission meetings sway EMA approval decisions

Drug firms’ pre-submission meetings with the EMA may influence agency approval decisions according to European Ombudsman Emily O' Reilly who has launched an investigation 

Emergent to buy Sanofi smallpox vaccine and take on CDC contract

Emergent BioSolutions will pay up to $125m (€108m) for Sanofi’s smallpox vaccine ACAM2000 in a deal that includes a plant and 10-year supply contract with the US Government.

Key Industry Events


Access all events listing

Our events, Shows & Conferences...